NCT06201247View on ClinicalTrials.gov

Off-the-shelf CD123 CAR-NK for R/R AML

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

December 30, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2025

Conditions
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Interventions
DRUG

JD123 injection

JD123 injection is an universal Off-the-shelf CD123-targeted chimeric antigen receptor modified natural killer cells (CAR-NK) therapy derived from a healthy donor.

Trial Locations (1)

100044

RECRUITING

Peking University People's Hospital, Beijing

All Listed Sponsors
lead

Peking University People's Hospital

OTHER